Revance Therapeutics, Inc. (RVNC)
NASDAQ: RVNC · IEX Real-Time Price · USD
3.655
+0.020 (0.55%)
Jul 22, 2024, 10:11 AM EDT - Market open
Revance Therapeutics Employees
Revance Therapeutics had 597 employees as of December 31, 2023. The number of employees increased by 63 or 11.80% compared to the previous year.
Employees
597
Change (1Y)
63
Growth (1Y)
11.80%
Revenue / Employee
$396,390
Profits / Employee
-$531,566
Market Cap
382.28M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Organogenesis Holdings | 862 |
uniQure | 480 |
AxoGen | 428 |
Lyell Immunopharma | 224 |
Sight Sciences | 214 |
Precigen | 202 |
TScan Therapeutics | 154 |
Lexeo Therapeutics | 58 |
RVNC News
- 5 weeks ago - Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 7 weeks ago - Revance to Participate in Upcoming Investor Conferences - Business Wire
- 2 months ago - Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update - Business Wire
- 2 months ago - Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia - Business Wire
- 2 months ago - Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024 - Business Wire
- 3 months ago - Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting - Business Wire
- 3 months ago - VKTX, JANX and these biotech stocks are surging in 2024 - Invezz
- 4 months ago - Revance Announces Pricing of $100.0 Million Public Offering of Common Stock - Business Wire